Young seal was found with ‘severe' shark bite wound. Then rescuers rushed to help
The animal, a New Zealand fur seal, was discovered in the canals of Newport, Australia, located about 20 miles north of Brisbane, according to a July 31 news release from the Sea World Foundation.
She had sustained 'a severe shark bite wound' on her abdomen and was outside the normal range of her species.
Sea World staffers collected the wounded creature and took her to a rehabilitation facility.
She 'was really touch and go there at the beginning,' Claire Madden, the organization's head veterinarian, said in a video.
But, after six weeks, her condition improved remarkably.
'She ticked all the boxes for our release, and that included adequate body condition, appropriate movement and her wound was completely resolved,' Madden said.
On July 29, the healed seal was transported to the Solitary Islands, part of a marine park about 240 miles south of Brisbane.
Video footage shows her exiting a submerged crate and swimming away into the deep ocean.
'It made me very, very happy to see her go back out there and carry on her little adventure,' Jesse Bray, a marine mammal specialist at the Sea World Foundation, said in the video. 'It's a really special moment.'
Before her release, she was equipped with a satellite tag, allowing researchers to monitor her journey. So far, she's already traveled about 50 miles south to Scotts Head.
New Zealand fur seals are distinguished by their pointy noses, long whiskers and relatively small size, according to the New Zealand Department of Conservation (DOC).
The marine mammals — which can grow up to 8 feet and weigh up to 330 pounds — are typically found along the rocky coast of New Zealand. They are also seen in South Australia and Western Australia.
Their population in New Zealand once numbered in the millions, according to the DOC, but they nearly went extinct as a result of Māori and European hunters. Nowadays, their numbers are rebounding, following protections passed in the 1970s.
They still face threats from human impacts, in addition to great white and sevengill sharks, their primary natural predators.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
7 hours ago
- Medscape
Do Women With Acute ACS Face Unnecessary Bleeding Risk?
A consensus statement from two European cardiology organizations contends antithrombotic treatment for myocardial infarction and angina overlooks sex differences that heighten bleeding risk in women. Compared with men, women treated for acute coronary syndromes (ACS) are at a greater risk for in-hospital bleeding related to invasive cardiac procedures and more long-term outpatient bleeding events, according to the statement from the European Association of Percutaneous Cardiovascular Interventions and the European Society of Cardiology Working Group on Thrombosis. Antithrombotic therapies such as heparin and fondaparinux used in invasive ACS procedures typically have a similar efficacy in women and men, but women have a higher bleeding risk of these agents, said Davide Capodanno, MD, PhD, professor of cardiology at the University of Catania, Catania, Italy, and co-author of the consensus statement. Some ways to reduce bleeding risk in women are to adjust antithrombotic dosing for body weight and kidney function, Capodanno told Medscape Medical News , and to opt for radial access over femoral access for percutaneous coronary intervention (PCI). 'Our paper shows that women still experience delays in diagnosis and treatment, receive excessive antithrombotic doses more often, and remain underrepresented in trials,' Capodanno said. 'All of this creates the need for clear, pragmatic, sex-informed recommendations.' Physiologic Differences Hormonal differences between men and women play an important role in bleeding risk. Estrogen promotes the production of prostacyclin, increases the availability of nitric oxide, and reduces platelet aggregation. These features might protect against the earlier onset of coronary artery disease, but fluctuations in hormonal status due to the menstrual cycle, use of oral contraceptives, menopause, and hormone replacement therapy can also influence thrombotic and bleeding risks. Sex differences in protease-activated receptor signaling pathways, smaller coronary artery sizes, and a cascade of other factors contribute to the greater risk for bleeding associated with ACS treatment (Figure). Although ACS typically affects postmenopausal women, the incidence is increasing in premenopausal women, whose bleeding risk is even more elevated because of lower platelet reactivity due to estrogen receptors on the platelet surface. Data from nearly 4000 women and 10,000 men undergoing PCI showed women younger than 50 years were four times more likely than men of the same age to experience major and minor bleeding events associated with stenting. Wanted: More Sex-Specific Data Women also often experience delays in the diagnosis of ACS and referral for invasive treatments, such as PCI, for their condition. Clinicians still lack strong evidence to help them address sex differences in clotting and response to anticoagulation, Capodanno suggested. Awareness is improving, but there's still work to be done. 'We simply don't have enough sex-powered data to guide all our decisions. Women remain underrepresented in clinical trials, which limits the strength of sex-specific evidence,' Capodanno said. 'We need to push for more equitable research by enrolling and retaining more women in clinical studies and ensuring that results are analyzed and published separately for men and women.' Sunil V. Rao, MD, lead author of the 2025 joint clinical practice guidelines on ACS from the American College of Cardiology and the American Heart Association, agreed. 'There are very few clinical trials of bleeding reduction that have strong female representation,' said Rao, deputy director of the Leon H. Charney Division of Cardiology and director of interventional cardiology at NYU Langone Heart in New York City. One such study, the SAFE-PCI for Women randomized trial Rao led, compared radial access and femoral access in women undergoing stenting. The research showed using radial instead of femoral access for the intervention reduces the risk for bleeding in women. 'We need more trials like this to help guide the clinical community on how to mitigate the risks of antithrombotic therapy in women,' Rao said. Take-Home: Male Isn't Norm How can individual clinicians adjust their practice? 'We recommend actively reducing bleeding risk — for example, using radial access whenever possible, using ultrasound guidance if femoral access is needed, and always avoiding overdosing by adjusting for weight and kidney function,' Capodanno said. Prompt treatment is key to avoid sex-related delays in starting antithrombotic medications. 'Also, be mindful of sex-specific presentations in ACS,' he added. Among these is myocardial infarction with nonobstructive coronary arteries, which includes spontaneous coronary artery dissection, responsible for 25%-35% of myocardial infarctions in women younger than 50 years. According to Rao, European guidelines are generally consistent with North American recommendations with respect to antithrombotic strategies for ACS. 'I don't think we can make strong recommendations to change practice just yet,' he said. 'The message really is to counsel patients, especially female patients, on the benefit-risk balance of antithrombotic therapy, to use evidence-based approaches to reduce bleeding risk — such as radial access — and to refer female patients for clinical trials when possible.' Capodanno reported payment for speaker fees and advisory board participation from Bristol Myers Squibb, Daiichi Sankyo, Novo Nordisk, Sanofi, and Terumo. Rao reported no relevant financial conflicts of interest.
Business Wire
7 hours ago
- Business Wire
ieso Sharpens Focus on AI-Powered Mental Healthcare with Sale of UK Telecare Services Business
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- ieso, a global leader in evidence-based digital mental health, today announced the sale of its UK telecare services business to Mindler, a leading pan-European digital therapy provider. The acquisition is specific to ieso's NHS-facing care operations in the UK, including delivery of typed and video therapy services. Mindler's press release is available here. "As AI adoption accelerates, mental health is emerging as one of its most urgent and natural use cases. The market is moving fast, and so are we." - Kent Tangen, CEO, ieso Share The parent company, ieso Digital Health Limited, remains fully independent and continues to operate under the ieso brand. With the sale now complete, ieso is entirely focused on scaling its clinical-grade generative AI platform, Velora, to deliver safe, effective, personalized mental health support via SaaS integration into clinical workflows. 'We're proud to have supported thousands of lives through ieso's UK telecare services. That legacy will always be a part of who we are,' said Kent Tangen, CEO at ieso. 'With those operations now in excellent hands at Mindler, ieso is committed to building the future we've long envisioned: delivering safe, effective AI-powered mental healthcare at scale. Our immediate focus is in the US, but our mission is global. As AI adoption accelerates, mental health is emerging as one of its most urgent and natural use cases. The market is moving fast, and so are we.' ieso was advised on the transaction by Cooley LLP and Artis Finance. About ieso ieso is a pioneer in AI-powered mental healthcare, combining clinical expertise with advanced technology to help more people feel better, faster. Its latest product, Velora, is a next-generation generative AI-based program that delivers outcomes on par with human-delivered care and is designed to integrate seamlessly into existing clinical workflows. Backed by over a decade of research and real-world data, ieso is focused on increasing access to safe, effective, and scalable mental health support in the US and beyond. To learn more or request a demo, visit
Time Business News
8 hours ago
- Time Business News
Ethical Considerations of Allowing People to köpa lustgas
In recent years, conversations around recreational substances have grown more complex. One substance that often enters this debate is nitrous oxide, more commonly referred to as 'laughing gas.' In some countries, this gas is used in medical and dental settings, but it is also sold in small canisters for recreational purposes. The practice of allowing individuals to köpa lustgas (buy nitrous oxide) raises ethical questions that go beyond simple legal regulation. Should people be free to purchase and use it as they wish, or do governments and societies have a responsibility to step in? To answer these questions, we need to look at the balance between personal freedom, public health, and ethical responsibility. Before diving into the ethical aspects, it's important to understand what nitrous oxide or lustgas—is. Medically, it is a colorless, odorless gas that has been used for centuries as an anesthetic and pain reliever. Dentists, for instance, often administer it to ease patient anxiety and discomfort. Outside of medical use, nitrous oxide is also found in whipped cream chargers and sometimes misused as a recreational inhalant. The euphoric effects are short-lived but can cause dizziness, impaired judgment, and in cases of repeated or heavy use serious health risks. When people are given the freedom to köpa lustgas, the line between medical utility and recreational misuse becomes blurred, sparking an ethical debate. One of the strongest arguments in favor of allowing individuals to köpa lustgas is the principle of autonomy. Autonomy emphasizes the right of individuals to make decisions about their own lives, provided those decisions don't cause direct harm to others. If an adult wishes to buy nitrous oxide and use it in private, supporters argue that it falls under personal choice. From this perspective, banning access could be seen as an infringement on individual freedom. After all, societies already allow people to make risky choices in other areas, such as consuming alcohol, smoking tobacco, or eating unhealthy foods. But autonomy has limits. Critics argue that true autonomy requires informed decision-making. If people do not fully understand the risks of nitrous oxide, can they really make a free and informed choice to use it? This is where the ethical complexity deepens. Beyond individual freedom lies the question of public health. Allowing unrestricted access to köpa lustgas might increase health risks within the wider community. Nitrous oxide misuse has been linked to vitamin B12 deficiency, nerve damage, and cognitive impairment. In extreme cases, improper handling can even cause suffocation. From an ethical standpoint, governments have a duty to protect public health. If widespread access to lustgas creates a measurable burden on healthcare systems, the argument for restricting or regulating sales becomes stronger. This reflects the principle of beneficence—acting in ways that promote the well-being of others. For example, some European countries have already introduced restrictions on sales to minors, recognizing the need to balance autonomy with public safety. A central ethical question is whether individuals truly understand the risks when they choose to köpa lustgas. In healthcare settings, informed consent is a cornerstone of ethical practice patients are told about the benefits and risks of a treatment before agreeing to it. However, outside of clinical environments, informed consent is less structured. A teenager buying nitrous oxide from a store may not be aware of potential long-term consequences. If people are not adequately educated about what they are purchasing, then society has failed in its ethical obligation to ensure informed decision-making. One potential solution is requiring clear labeling, public awareness campaigns, and restrictions on how the product is marketed. This way, people are empowered with knowledge while still maintaining a degree of autonomy. The ethical debate around whether to köpa lustgas often draws comparisons to other legal substances. Alcohol, for example, is widely available despite its well-documented health risks and social harms. Tobacco is similar though heavily regulated, it is still legal to purchase and consume. If society permits these substances, some argue it would be inconsistent or even hypocritical to ban nitrous oxide outright. On the other hand, opponents contend that just because one harmful substance is legal doesn't mean others should automatically follow the same path. Ethics isn't about consistency alone, it's about weighing risks, benefits, and responsibilities in each unique case. Another ethical layer emerges when considering vulnerable groups. Young people, for instance, may be particularly drawn to nitrous oxide for its cheap price and quick effects. Without life experience or risk awareness, minors may be more susceptible to harm. Allowing unrestricted access to köpa lustgas could unintentionally target these groups, raising questions about exploitation and fairness. Ethically, societies often place greater protections around vulnerable populations, whether in terms of labor laws, alcohol restrictions, regulations. Nitrous oxide should arguably be no different. The ethics of köpa lustgas don't only involve the buyers; sellers also bear responsibility. Should businesses be able to profit from a substance that carries known risks? Or should they be required to implement safeguards, such as age restrictions and responsible sales practices? In this context, we can draw parallels to alcohol vendors, who must refuse sales to minors, or pharmacies, which control access to certain medications. Ethical commerce requires balancing profit motives with social responsibility. Sellers of nitrous oxide should not be exempt from these considerations. Ethical debates are rarely one-size-fits-all. The decision to allow people to köpa lustgas is influenced by cultural attitudes toward substances in general. Some societies emphasize strict control and prohibition, while others prioritize personal liberty and harm-reduction strategies. For example, harm-reduction approaches suggest that instead of banning substances, governments should regulate and educate to minimize risks. This philosophy treats individuals as capable of making choices, provided they are supported with accurate information and safe environments. Prohibitionist approaches, by contrast, argue that the risks are too great, and society has a duty to prevent harm by removing access entirely. The ethical debate shifts depending on which cultural lens is applied. Ultimately, the ethics of allowing people to köpa lustgas come down to balancing freedom with responsibility. Total prohibition might protect public health but could infringe on personal autonomy. Unrestricted access, however, might respect individual choice while leading to preventable harm. The most ethically defensible approach likely lies somewhere in between: regulated access, age restrictions, public education, and seller accountability. This framework respects personal freedom while minimizing risks, reflecting a more nuanced understanding of ethics in practice. The question of whether people should be allowed to köpa lustgas is not just a legal issue, it is a deeply ethical one. It forces us to examine how we value autonomy, public health, informed consent, and the protection of vulnerable populations. While there may never be a perfect answer, a balanced approach that combines regulation with education appears to honor both individual rights and collective well-being. As with many ethical debates, the challenge is not in choosing between freedom and safety but in finding a path that respects both. TIME BUSINESS NEWS
